-- "Your Journey. Our Mission.™" communicates company's new
brand promise
BOSTON, Feb. 12, 2014 /PRNewswire/ -- As the global
biopharmaceutical industry increasingly seeks to streamline the
complex process of bringing new drugs to market, PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced the launch of
a new marketing initiative that highlights the Company's proven
approach to help clients simplify the journey from science to new
treatments.
Drug development today is a demanding and difficult process.
Increasingly, pharmaceutical companies are under pressure to
accelerate development and introduce innovative new medicines and
treatments in an increasingly complex and competitive environment.
To assist in these efforts, companies are seeking a partner that
can help simplify and accelerate all aspects of product
development.
"In today's market, biopharmaceutical companies must effectively
balance global requirements with regional and local issues, address
clinical trial complexity and seek ways to make the drug
development process more efficient," said Josef von Rickenbach, Chairman and Chief
Executive Officer, PAREXEL International. "For more than 30 years,
our mission has been to help the biopharmaceutical and medical
device industries prevent and cure disease. While that mission
hasn't changed, the way we promote our mission is changing.
PAREXEL's new brand platform clearly defines how we can simplify
drug development by applying our unique capabilities to the work we
do. This will help clients better understand the full scope of our
portfolio, and how individual offerings interrelate."
Your Journey. Our Mission.™
PAREXEL's new brand promise, "Your Journey. Our
Mission™ ," represents the Company's commitment to
make each client's journey its mission. The Company works to
fulfill this commitment through its:
- Global Expertise: Today, it is not enough to have a
large global footprint. PAREXEL's drug development experts are
connected through common processes, standards and technology, so
regardless of where a study is conducted, the same standards of
quality apply. With 76 locations in 50 countries, PAREXEL
cooperates and collaborates globally to provide services and share
best practices around the world. PAREXEL brings value to clients
throughout the entire product life cycle by putting to work its
deep understanding of science, technology, regulatory and business
issues combined with global resources and local knowledge of
region-specific requirements.
- Drive to Solve the Complex: From its fully integrated
Perceptive MyTrials®eClinical technology platform to its pioneering
regulatory work in biosimilars, PAREXEL is constantly working to
solve complex challenges for clients by optimizing integrated
offerings in new and innovative ways.
- Recognition of the Bigger Journey: PAREXEL led the
development of Strategic Partnerships in the biopharmaceutical
industry, enabling companies to optimize the entire drug
development process. These close, long-term partnerships drive
deeper collaboration, speed up development cycles and reduce cost,
according to PAREXEL's Strategic Partnerships 2013 report.
It revealed that 85 percent of the biopharmaceutical executives
surveyed believe Strategic Partnerships have positively impacted
CRO-sponsorship relationships.
As part of its global marketing and advertising campaign,
PAREXEL has also launched a new corporate website that provides an
enhanced visitor experience, more clearly distinguishes PAREXEL's
products and services, and communicates the Company's true value to
clients. The website features several videos that illustrate
the company's global expertise as well as its ability to manage
complexity and develop meaningful Strategic Partnerships.
"We believe the world will be a healthier place when the journey
between science and new treatments becomes simpler," said
Christopher Tama, Worldwide Head of
Marketing, PAREXEL. "This belief is the foundation of our story,
which we are now beginning to tell in new and creative
ways."
About PAREXEL International
PAREXEL
International Corporation is a leading global biopharmaceutical
services organization, providing a broad range of knowledge-based
contract research, consulting, medical communications, and
technology solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. Perceptive
Informatics, Inc., a subsidiary of PAREXEL, provides advanced
technology solutions to facilitate the clinical development
process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 76 locations in 50
countries around the world, and has 15,100 employees. For
more information about PAREXEL International, visit
www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, Perceptive MyTrials,
Perceptive Informatics, and "Your Journey. Our Mission." are
trademarks or registered trademarks of PAREXEL International
Corporation or its affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ significantly from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Company's
Quarterly Report on Form 10-Q for the fiscal quarter ended
December 31, 2013 as filed with the
SEC on January 31, 2014, which "Risk
Factors" discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
Vice President, Corporate Communications
PAREXEL International
Tel: +1-781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1-617-502-4300
Email: PAREXEL@pancomm.com